Literature DB >> 31012354

QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors.

S Sanyal1, S A Amin1, N Adhikari1, T Jha1.   

Abstract

Matrix metalloproteinase-2 (MMP-2) is a lucrative therapeutic target as far as anticancer drug discovery is concerned. Overexpression of MMP-2 is found to facilitate tumour propagation through the involvement of vascular endothelial growth factor (VEGF). However, even after different techniques, finding a target-specific MMP-2 inhibitor with respectable pharmacodynamic properties is still a challenging task. Regression-dependent quantitative structure-activity relationship (QSAR) strategies might be among the possible drug design methods to explore the essential structural features that would be valuable to find a suitable MMP-2 inhibitor. In this paper, 72 molecules were explored using the PaDEL descriptors and stepwise multiple linear regression (S-MLR). The partial least squares (PLS) method was also used to create a viable statistical model with an acceptable metric related to these models. The final statistical models were formed with statistical parameters within acceptable range (r2 = 0.797, Q2 = 0.725 and r2pred = 0.643 for the MLR model, and r2 = 0.780, Q2 = 0.685 and r2pred = 0.666 for the PLS model). The models were analysed and compared with those already published on the same endpoint.

Entities:  

Keywords:  MMP-2; PLS; PaDEL-descriptor; QSAR; S-MLR; arylsulfonamide hydroxamate

Mesh:

Substances:

Year:  2019        PMID: 31012354     DOI: 10.1080/1062936X.2019.1588159

Source DB:  PubMed          Journal:  SAR QSAR Environ Res        ISSN: 1026-776X            Impact factor:   3.000


  1 in total

1.  In-silico modelling studies of 5-benzyl-4-thiazolinone derivatives as influenza neuraminidase inhibitors via 2D-QSAR, 3D-QSAR, molecular docking, and ADMET predictions.

Authors:  Mustapha Abdullahi; Adamu Uzairu; Gideon Adamu Shallangwa; Paul Andrew Mamza; Muhammad Tukur Ibrahim
Journal:  Heliyon       Date:  2022-08-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.